Nanjing Sinolife United Co., Ltd. Class H (3332) AI Stock Analysis

• Market Cap: HK$664.25M
• Dividend Yield: N/A
• Average Volume (3M): 124.27K
• Price to Earnings (P/E): 21.9
• Beta (1Y): -0.28
• Revenue Growth: -0.92%
• EPS Growth: -71.88%
• Country: HK
• Employees: 468
• Sector: Financial
• Sector Strength: 71
• Industry: Household & Personal Products
• EPS (TTM): 0.02
• Shares Outstanding: 946,298,340
• 10 Day Avg. Volume: 180,600
• 30 Day Avg. Volume: 124,266
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$0.50
• Price Target Upside: 21.95% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: HK$0.50 ▲(21.95% Upside)

The overall stock score is primarily influenced by the company's strong financial performance, despite concerns about cash flow data. Technical analysis indicates bearish momentum, and valuation is moderate with no dividend yield. The lack of earnings call data and corporate events limits additional insights.

Nanjing Sinolife United Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Nanjing Sinolife United Co., Ltd. Class H (3332) is a Chinese company primarily engaged in the research, development, manufacturing, and distribution of health-related products. The company's offerings include nutritional supplements, functional foods, and health care products, catering to a wide range of consumer health needs. Sinolife United operates within the health and wellness sector, focusing on providing high-quality products that promote a healthier lifestyle.

How the Company Makes Money

Nanjing Sinolife United Co., Ltd. generates revenue through the sale of its health-related products, which include nutritional supplements and functional foods. The company's primary revenue streams come from domestic sales in China, as well as international sales through its distribution networks. Sinolife United capitalizes on its research and development capabilities to innovate and create new products that meet consumer demands. Additionally, the company may engage in strategic partnerships with other businesses in the health sector to expand its market reach and enhance its product offerings, contributing to its overall earnings.

Nanjing Sinolife United Co., Ltd. Class H Financial Statement Overview

Summary

The company shows strong revenue growth and improving profitability with a robust balance sheet characterized by low leverage and high equity. However, the lack of recent cash flow data presents a potential risk to liquidity and cash management.

Income Statement

The company has shown a significant improvement in gross profit margin from the previous year, rising from 67.34% to 71.95%. Net profit margin also improved from 9.33% to 4.62%, indicating better operational efficiency. Revenue growth rate from 2023 to 2024 was a substantial 32.53%, showing strong sales performance. However, EBIT and EBITDA margins decreased slightly, signaling some pressure on operating profitability.

Balance Sheet

The company maintains a strong equity base with an equity ratio of 77.96%, reflecting stability. The debt-to-equity ratio is low at 0.09, indicating conservative leverage. Return on equity is modest at 8.77%, suggesting room for improvement in generating shareholder returns. Overall, the balance sheet shows stability with low financial risk.

Cash Flow

The cash flow statement shows a concerning lack of operating cash flow in the latest year, which could impact liquidity. Previously, free cash flow showed growth, but the absence of cash flow data for 2024 raises concerns about cash management. Free cash flow to net income and operating cash flow to net income ratios are unavailable, limiting the assessment of cash conversion efficiency.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	747.90M	563.96M	274.85M	252.32M	296.52M
Gross Profit	538.27M	379.66M	160.00M	138.80M	170.70M
EBITDA	48.19M	75.08M	4.88M	-13.49M	-20.96M
Net Income	34.56M	52.60M	-14.25M	-31.71M	-49.60M
Balance Sheet
Total Assets	505.56M	505.42M	436.99M	390.11M	449.73M
Cash, Cash Equivalents and Short-Term Investments	104.53M	122.79M	73.39M	72.06M	77.12M
Total Debt	33.90M	35.16M	35.75M	8.87M	13.46M
Total Liabilities	111.46M	127.35M	113.19M	59.87M	87.37M
Stockholders Equity	394.10M	378.07M	323.80M	330.24M	362.36M
Cash Flow
Free Cash Flow	-6.65M	44.76M	4.05M	-9.68M	3.20M
Operating Cash Flow	957.00K	47.11M	7.92M	421.00K	16.41M
Investing Cash Flow	-6.00M	449.00K	-3.47M	1.52M	-12.49M
Financing Cash Flow	-4.53M	-4.50M	-4.08M	-4.45M	-34.05M

Nanjing Sinolife United Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3332, the sentiment is Negative. The current price of 0.41 is below the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.45, and below the 200-day MA of 0.52, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.01 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3332.

Nanjing Sinolife United Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3828	73 Outperform	HK$677.82M	4.78	10.86%	10.75%	6.86%	18.44%
Sector *	68 Neutral	$17.81B	11.87	10.24%	3.74%	9.75%	1.30%
2023	62 Neutral	HK$393.44M	6.91	10.92%	―	11.10%	-4.38%
2177	56 Neutral	HK$376.58M	14.13	3.32%	22.03%	-9.26%	435.33%
3332	54 Neutral	HK$664.25M	21.93	3.92%	―	-0.92%	-71.88%
NBBTF	―	$143.81M	―	-12.38%	―	―	―
2138	57 Neutral	HK$960.02M	19.67	-8.91%	1.23%	-1.68%	-781.88%

Nanjing Sinolife United Co., Ltd. Class H Corporate Events

Nanjing Sinolife United Announces Board Meeting for Interim Results

Nanjing Sinolife United Co., Ltd. has announced that its board of directors will meet on August 22, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend and address other business matters. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, as the board will evaluate financial performance and potential dividend distribution, which could impact investor sentiment and market perception.

Nanjing Sinolife Issues Profit Warning Amid Revenue Decline

Nanjing Sinolife United Co., Ltd. has issued a profit warning, indicating a significant decrease in net profit for the first half of 2025 compared to the same period in 2024. The decline is attributed to reduced revenue from distributor channels for infant and child products in Mainland China and increased marketing expenses on e-commerce platforms. The company’s interim results are yet to be finalized, and stakeholders are advised to exercise caution.

Nanjing Sinolife United Co., Ltd. Enhances Board Governance with New Nomination Committee

Nanjing Sinolife United Co., Ltd. has established a Nomination Committee to enhance its board composition and corporate governance. The committee is tasked with selecting candidates for directors and management, reviewing board structure, and making recommendations on appointments and succession planning, thereby strengthening the company’s strategic direction and operational oversight.

Nanjing Sinolife United Co., Ltd. AGM Resolutions Unanimously Approved

Nanjing Sinolife United Co., Ltd. held its Annual General Meeting on June 6, 2025, where all proposed resolutions were unanimously approved by shareholders. Key resolutions included the approval of the company’s financial reports for 2024, the decision not to distribute profits for that year, and the reappointment of Ernst & Young as auditors. Additionally, a special resolution was passed granting the board a mandate to issue additional H shares, reflecting a strategic move to potentially expand the company’s capital structure.